Europe Human Insulin Drugs and Delivery Devices Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Europe Human Insulin Drugs and Delivery Devices Market Segmentation, By Drugs (Basal or Long Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, Combination Insulins and Biosimilar Insulins), Device (Insulin Pumps, Insulin Pens, Insulin Syringes and Insulin Jet Injectors), Delivery Devices (Syringes, Pens and Pen Needles), Application (Type II Diabetes and Type II Diabetes), Product (HI Drugs, HI Delivery Devices), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics/ Centers and Other), End User (Hospitals and Clinics, Homecare and Specialty Centers),- Industry Trends and Forecast to 2032

Europe Human Insulin Drugs and Delivery Devices Market Size

• The Europe Human Insulin Drugs and Delivery Devices Market size was valued at USD 4.37 billion in 2024 and is expected to reach USD 6.79 billion by 2032, at a CAGR of 5.68% during the forecast period
• The market growth is largely fueled by the rising prevalence of diabetes, increasing awareness about insulin therapy, and technological advancements in drug delivery systems, leading to improved patient compliance and therapeutic outcomes
• Furthermore, growing demand for user-friendly, safe, and effective insulin administration methods is driving the adoption of advanced human insulin drugs and delivery devices. These factors are accelerating the uptake of innovative insulin pens, pumps, and digital delivery solutions, thereby significantly boosting the industry's growth

Europe Human Insulin Drugs and Delivery Devices Market Analysis

• Human insulin drugs and delivery devices, offering precise and controlled administration of insulin, are increasingly vital components of modern diabetes management in both clinical and homecare settings due to their enhanced dosing accuracy, ease of use, and integration with patient monitoring systems
• The escalating demand for human insulin drugs and delivery devices in Europe is primarily driven by the increasing prevalence of diabetes, rising awareness of effective disease management, and the adoption of advanced insulin delivery technologies across hospitals and homecare settings
• Germany dominated the Europe Human Insulin Drugs and Delivery Devices Market with the largest revenue share of 34.5% in 2024, supported by a robust pharmaceutical and healthcare industry, high adoption of insulin pumps and pens, and strong hospital infrastructure. Widespread use of advanced delivery devices in clinical settings and homecare continues to strengthen Germany’s market leadership
• France is expected to be the fastest-growing country in the Europe Human Insulin Drugs and Delivery Devices Market during the forecast period, fueled by expanding healthcare access, growing diabetes awareness programs, and rapid adoption of modern insulin delivery devices, including smart pens and pumps, in clinical and personal use
• The Human Insulin Drugs segment dominated the Europe Human Insulin Drugs and Delivery Devices Market with the largest revenue share of 54.1% in 2024, driven by the essential role of insulin in both type I and type II diabetes management. High prevalence, long-term therapy requirements, and clinical recommendations contribute to dominance

Report Scope and Europe Human Insulin Drugs and Delivery Devices Market Segmentation 

Europe Human Insulin Drugs and Delivery Devices Market Trends

Enhanced Convenience Through Advanced Delivery and Monitoring Systems

• A significant and accelerating trend in the Europe Human Insulin Drugs and Delivery Devices Market is the increasing integration of advanced delivery mechanisms and digital monitoring systems, significantly improving dosing accuracy, patient compliance, and ease of use
• For instance, smart  insulin pens and pumps are now equipped with smart dosing reminders, connectivity to mobile apps, and cloud-based monitoring, enabling patients and healthcare providers to track insulin administration in real time
• Continuous glucose monitoring (CGM)-linked insulin delivery devices allow for dynamic adjustment of insulin dosage based on real-time glucose readings, reducing the risk of hypoglycemia and improving overall glycemic control
• The integration of these devices with healthcare IT systems and mobile platforms facilitates centralized tracking of patient data, supporting personalized therapy plans and better disease management
• This trend toward more intelligent, connected, and user-friendly delivery devices is reshaping patient expectations and healthcare standards in Europe
• Consequently, leading companies in the market are developing innovative insulin delivery systems that combine accuracy, portability, and remote monitoring feature
• The demand for these advanced devices is growing rapidly across both hospital and homecare settings, driven by the increasing prevalence of diabetes and the focus on improving quality of life for patients

Europe Human Insulin Drugs and Delivery Devices Market Dynamics

Driver

Growing Need Due to Rising Diabetes Prevalence and Advancements in Delivery Systems

• The increasing prevalence of diabetes across Europe, coupled with the rising demand for accurate and convenient insulin delivery solutions, is a significant driver for the growth of the Europe Human Insulin Drugs and Delivery Devices Market
• For instance, in 2024, Novo Nordisk announced the construction of a new insulin manufacturing facility in Kalundborg, Denmark, aimed at increasing the production of human insulin and insulin analogs to meet growing demand across Europe. This expansion reflects the rising need for reliable insulin supply due to the increasing prevalence of diabetes in European countries
• As patients become more aware of the importance of glycemic control, advanced insulin delivery devices offer features such as precise dose management, automatic reminders, and real-time tracking, providing a compelling improvement over traditional syringe
• Furthermore, the growing adoption of mobile health applications and connected monitoring platforms is making these devices more accessible and easier to integrate into daily routines, allowing for better adherence to therapy plans
• The convenience of prefilled pens, patch pumps, and portable delivery systems, along with the ability to monitor glucose levels remotely, are key factors propelling the adoption of these devices across both hospital and homecare settings
• The trend towards more user-friendly, accurate, and connected insulin delivery solutions is further supported by patient education and healthcare provider initiatives, ensuring wider acceptance and proper usage

Restraint/Challenge

Concerns Regarding Device Cost and Integration

• One of the primary challenges restraining the growth of the Europe Human Insulin Drugs and Delivery Devices Market in Europe is the relatively high initial cost of advanced insulin delivery systems. Many patients, particularly those in regions with limited healthcare reimbursement or lower income levels, may find it difficult to afford premium devices, which can slow adoption despite their clinical benefits
•  Another key barrier is the complexity of integrating these devices with digital monitoring platforms and healthcare management systems. Patients and healthcare providers may face a learning curve in using connected apps, interpreting data, or linking devices to broader care programs, which can limit immediate uptake
• Training and education requirements further contribute to the adoption challenge. Some patients, especially the elderly or those unfamiliar with technology, may struggle with device setup, maintenance, and proper use, necessitating additional support from healthcare professionals or the manufacturers themselves
• While companies are responding by developing more cost-effective, user-friendly devices with simplified interfaces and step-by-step guidance, the perception of high costs and complexity continues to hinder widespread acceptance
• Overcoming these obstacles through strategies such as subsidized pricing, comprehensive patient education programs, and seamless integration with digital health platforms will be critical for the sustained expansion of the European Europe Human Insulin Drugs and Delivery Devices Market

Europe Human Insulin Drugs and Delivery Devices Market Scope

The market is segmented on the basis of drugs, devices, delivery devices, application, product, distribution channel, and end user.

• By Drugs

On the basis of drugs, the Europe Human Insulin Drugs and Delivery Devices Market is segmented into basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins. The basal or long-acting insulins segment dominated the largest market revenue share of 45.3% in 2024, driven by the rising prevalence of type II diabetes in Europe and the demand for insulins that provide stable, long-term glycemic control. These insulins are preferred for their once-daily administration, lower risk of hypoglycemia, and ability to maintain consistent blood glucose levels. Adoption is further supported by clinical guidelines recommending basal insulins as the backbone of type II diabetes management. Their ease of use, patient adherence benefits, and integration with modern delivery devices make them highly popular among healthcare providers. Long-acting insulins are widely used in hospital and homecare settings, ensuring continuous therapy for adult and geriatric populations.

The biosimilar insulins segment is expected to witness the fastest CAGR of 11.2% from 2025 to 2032, fueled by the increasing emphasis on cost-effective diabetes management and growing regulatory approvals for biosimilar products. The segment benefits from expanding accessibility in emerging European markets and rising awareness among physicians and patients regarding biosimilar efficacy and safety. Cost savings compared to originator insulins make biosimilars attractive for government and private healthcare programs. Rising partnerships between biosimilar manufacturers and distributors are also enhancing availability. In addition, the growing incidence of type I and type II diabetes and focus on equitable healthcare access support rapid uptake.

• By Device

On the basis of device, the Europe Human Insulin Drugs and Delivery Devices Market is segmented into insulin pumps, insulin pens, insulin syringes, and insulin jet injectors. The Insulin Pens segment held the largest revenue share of 41.7% in 2024, due to their ease of use, portability, and precise dosing capabilities. Prefilled pens allow patients to self-administer insulin safely with minimal training, improving adherence and quality of life. Pens are preferred for outpatient and homecare settings, reducing injection errors and improving convenience compared to syringes. Their compact design, compatibility with multiple insulin types, and patient-friendly features such as dose memory support high adoption. Pens are widely used across adult and geriatric populations, supporting long-term diabetes management. Healthcare providers favor pens for both basal and bolus insulin administration in clinical practice.

The insulin pumps segment is expected to witness the fastest CAGR of 12.1% from 2025 to 2032, driven by increasing demand for continuous insulin delivery and advanced glycemic control. Pumps provide programmable, personalized insulin dosing, helping patients maintain target glucose levels. Integration with continuous glucose monitoring (CGM) systems enables real-time data-driven insulin adjustments. Rising awareness among patients and clinicians about the benefits of pump therapy in type I and insulin-dependent type II diabetes contributes to growth. Technological advancements, improved ease of use, and reimbursement policies in Europe further accelerate adoption. Pumps are increasingly preferred in specialized diabetes centers and pediatric care settings.

• By Delivery Devices

On the basis of delivery devices, the Europe Human Insulin Drugs and Delivery Devices Market is segmented into syringes, pens, and pen needles. The pen segment dominated with a 47.5% revenue share in 2024, owing to its convenience, patient-friendliness, and precision in insulin dosing. Prefilled and reusable pens reduce preparation errors and improve adherence, especially among elderly and visually impaired patients. Pens support a wide range of insulin types, enabling both basal and bolus administration. High adoption in homecare, outpatient, and clinical settings contributes to market dominance. Healthcare providers favor pens for patient safety and ease of instruction. The widespread availability of pens in pharmacies and clinics ensures consistent supply for chronic management.

The pen needles segment is expected to witness the fastest CAGR of 10.8% from 2025 to 2032, driven by the increasing number of insulin users and focus on improving injection comfort. Shorter, thinner, and safer needles enhance patient adherence and reduce pain and fear associated with injections. Pen needle innovations, including protective caps and ultra-thin designs, encourage repeat use. Growing adoption of pens and rising awareness about proper injection techniques further support segment growth. The segment also benefits from educational programs by diabetes associations emphasizing correct needle use.

• By Application

On the basis of application, the Europe Human Insulin Drugs and Delivery Devices Market is segmented into Type I Diabetes and Type II Diabetes. The Type II Diabetes segment accounted for the largest market revenue share of 63.4% in 2024, reflecting the high prevalence of type II diabetes among European adults. Rising obesity, sedentary lifestyles, and aging populations drive insulin therapy requirements for type II diabetes. Basal and combination insulins are widely administered in hospitals, clinics, and homecare, contributing to market dominance. Awareness campaigns and government health initiatives targeting diabetes management further support adoption. Treatment guidelines recommending early insulin initiation for type II diabetes enhance demand. Homecare delivery and patient self-management programs are also increasingly implemented.

The Type I Diabetes segment is expected to witness the fastest CAGR of 9.7% from 2025 to 2032, supported by increasing diagnosis in younger populations and the growing adoption of advanced insulin delivery devices. The segment benefits from integration with insulin pumps and continuous glucose monitoring systems. Rising patient awareness, early diagnosis programs, and specialized diabetes care centers contribute to rapid growth. Type I diabetes management often requires intensive insulin therapy, driving higher usage of pumps and pens. Expansion of pediatric diabetes programs and hospital-based initiatives also supports segment adoption.

• By Product

On the basis of product, the Europe Human Insulin Drugs and Delivery Devices Market is segmented into human insulin drugs and human insulin delivery devices. The human insulin drugs segment held the largest revenue share of 54.1% in 2024, driven by the essential role of insulin in both type I and type II diabetes management. High prevalence, long-term therapy requirements, and clinical recommendations contribute to dominance. Drugs are widely supplied through hospitals, retail pharmacies, and diabetes clinics. The growing adoption of combination insulins and biosimilars also supports revenue. Government health programs ensure consistent availability, especially for chronic care patients.

The human insulin delivery devices segment is expected to witness the fastest CAGR of 10.5% from 2025 to 2032, supported by technological advancements in pens, pumps, and needle designs. Rising patient preference for user-friendly, accurate, and convenient delivery solutions accelerates growth. The segment benefits from increasing homecare adoption and continuous innovation in device safety and ergonomics. Integration with digital health platforms and patient monitoring apps enhances usability. Rising awareness among healthcare professionals and patients about improved compliance through advanced devices drives adoption.

• By Distribution Channel

On the basis of distribution channel, the Europe Human Insulin Drugs and Delivery Devices Market is segmented into hospital pharmacy, retail pharmacy, online sales, diabetes clinics/centers, and other. The hospital pharmacy segment dominated with a 51.8% share in 2024, driven by the large-scale procurement of insulin drugs and delivery devices by hospitals and specialty centers for both inpatient and outpatient diabetes management. Hospital pharmacies provide patients with direct access to a wide range of insulin therapies and delivery devices, ensuring adherence to prescribed regimens. The segment benefits from bulk purchasing agreements, long-term procurement contracts, and strategic partnerships with suppliers, which help maintain a consistent supply of high-quality products. Government-supported health programs and private hospital initiatives further reinforce the adoption of insulin therapies through hospital pharmacies. In addition, hospital pharmacies offer clinical guidance and patient education, ensuring safe and effective administration of insulin. The integration of advanced delivery devices such as pens and pumps in hospital settings improves dosing accuracy and patient compliance.

The online sales segment is expected to witness the fastest CAGR of 12.3% from 2025 to 2032, fueled by the rapid growth of e-pharmacy platforms, convenient home delivery services, and increasing patient preference for digital purchasing channels. Online sales provide homecare patients with quick access to a variety of insulin drugs and devices, supporting self-administration and adherence. Subscription-based delivery models, timely replenishment services, and partnerships with logistics providers enhance accessibility and convenience. Rising adoption of digital healthcare platforms and mobile applications allows patients to monitor orders, manage deliveries, and receive timely reminders. The segment also benefits from marketing campaigns by suppliers that educate patients on product options and proper use. Increasing tech-savviness among patients and caregivers, along with the growing focus on chronic disease management at home, further drives growth in the online sales channel.

• By End User

On the basis of end user, the Europe Human Insulin Drugs and Delivery Devices Market is segmented into hospitals and clinics, homecare, and specialty centers. The hospitals and clinics segment held the largest revenue share of 56.7% in 2024, reflecting the high reliance on hospital infrastructure for insulin therapy administration. Hospitals and clinics serve as key points for prescription fulfillment, direct administration of insulin, and patient training programs. The segment benefits from bulk procurement, strategic supplier contracts, and government or private programs promoting standardized diabetes care. Integration of advanced insulin delivery devices in clinical settings ensures precise dosing, improves treatment adherence, and minimizes risks associated with improper administration. In addition, hospitals and clinics provide ongoing monitoring and follow-up, which are essential for long-term diabetes management. The presence of specialized diabetes care units and trained medical personnel further reinforces the dominance of this segment in Europe.

The homecare segment is expected to witness the fastest CAGR of 11.4% from 2025 to 2032, driven by growing patient preference for self-management, convenience, and independence in insulin administration. The adoption of insulin pens, pumps, and other user-friendly delivery devices enables safe and accurate self-administration at home. Homecare growth is supported by remote monitoring solutions, patient education programs, and digital health platforms that help track glucose levels, insulin dosing, and treatment adherence. Increasing awareness about the benefits of homecare management and ongoing government or private support programs for chronic disease care also contribute to the expansion of this segment. The trend toward home-based healthcare, coupled with the convenience of accessible delivery of insulin drugs and devices, strengthens the rapid adoption of homecare services across Europe.

Europe Human Insulin Drugs and Delivery Devices Market Regional Analysis

• The Europe Human Insulin Drugs and Delivery Devices Market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by the strong presence of the pharmaceutical and healthcare industries, increasing prevalence of diabetes, and rising adoption of advanced insulin delivery systems such as pumps and smart pens
• Germany dominated the Europe Human Insulin Drugs and Delivery Devices Market with the largest revenue share of 34.5% in 2024, supported by a robust pharmaceutical and healthcare industry, high adoption of insulin pumps and pens, and strong hospital infrastructure. Widespread use of advanced delivery devices in clinical settings and homecare continues to strengthen Germany’s market leadership
• France is expected to be the fastest-growing country in the Europe Human Insulin Drugs and Delivery Devices Market during the forecast period, fueled by expanding healthcare access, growing diabetes awareness programs, and rapid adoption of modern insulin delivery devices, including smart pens and pumps, in clinical and personal use

Germany Europe Human Insulin Drugs and Delivery Devices Market Insight

The Germany Europe Human Insulin Drugs and Delivery Devices Market is expected to expand at a considerable CAGR during the forecast period, dominated by the country with the largest revenue share of 34.5% in 2024. The growth is supported by a well-established pharmaceutical and healthcare sector, high adoption of insulin pumps and pens, and strong hospital infrastructure. Widespread use of advanced insulin delivery devices in clinical settings and homecare continues to strengthen Germany’s market leadership. In addition, Germany’s emphasis on technological innovation, patient-centric care, and integration of devices with digital health monitoring platforms is driving adoption across hospitals, clinics, and personal use, making it the key contributor to Europe’s market.

France Europe Human Insulin Drugs and Delivery Devices Market Insight

The France Europe Human Insulin Drugs and Delivery Devices Market is expected to be the fastest-growing country in the European Europe Human Insulin Drugs and Delivery Devices Market during the forecast period, fueled by expanding healthcare access, increasing diabetes awareness initiatives, and rapid adoption of modern insulin delivery systems including smart pens and pumps. Growth is further supported by rising patient education programs, government initiatives to improve chronic disease management, and the increasing availability of digital monitoring-enabled devices. The country’s focus on enhancing patient convenience and improving disease management outcomes is driving higher adoption across both clinical and homecare settings, positioning France as the fastest-growing market in Europe.

Europe Human Insulin Drugs and Delivery Devices Market Share

The human insulin drugs and delivery devices industry is primarily led by well-established companies, including:

• Novo Nordisk A/S (Denmark)
• Sanofi (France)
• Lilly USA, LLC. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Insulet Corporation (U.S.)
• Medtronic (Ireland)
• Ypsomed AG (Switzerland)
• Abbott Laboratories (U.S.)
• MannKind Corporation (U.S.)
• Tandem Diabetes Care, Inc. (U.S.)
• Vetter Pharma International GmbH (Germany)
• Biocon Limited (India)
• Wockhardt Limited (India)
• Shenzhen Keling Medical Co., Ltd. (China)
• SOOIL Development Co., Ltd. (South Korea)
• Ascensia Diabetes Care Holdings AG (Switzerland)
• Hugel, Inc. (South Korea)
• Haselmeier (Germany)

Latest Developments in Europe Human Insulin Drugs and Delivery Devices Market

• In January 2025, Insulet Corporation announced the launch of its Omnipod 5 Automated Insulin Delivery System in five additional European countries: Italy, Denmark, Finland, Norway, and Sweden. This expansion integrates Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 continuous glucose monitoring systems, enhancing the system's automated insulin delivery capabilities
• In July 2025, Diabeloop, in collaboration with SOOIL, launched the DBLG1 system in Germany, utilizing the Dana-i insulin pump. This system integrates with the Dexcom G7 continuous glucose monitor and is distributed by Mediq. The upcoming DBLG2 version, which will be available on patients' smartphones, is also planned for release in Europe
• In August 2024, Sanofi announced a EUR 1.3 billion investment to construct a new insulin production facility in Frankfurt, Germany. The 36,000-square-meter plant is set to replace the current facility by 2029 and will continue the production of Lantus, Sanofi's long-acting insulin
• In January 2024, Medtronic announced plans to release the MiniMed 780G insulin pump system with Simplera Sync in Europe through a limited release in spring 2024. The system aims to provide enhanced glucose control for individuals with type 1 diabetes
• In June 2022, Diabeloop secured EUR 70 million in new financing to accelerate its international expansion of its AI-driven insulin delivery systems. The company also reported significant improvements in patient outcomes, including an 18.4% increase in Time in Range and a reduction in hypoglycemia to 0.9% with its DBLG1 system

SKU-1953